vonaprument
vonaprument: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Annexon, Inc. (ANNX) | Phase 3 |
Clinical Trials (1)
A Phase 3, Multicenter, Randomized, Parallel-Group, Double-Masked, 2-Arm, Sham Controlled Study of the Efficacy, Safety, and Tolerability of ANX007 (Vonaprument) Administered by Intravitreal Injection in Participants With Dry Age-Related Macular Degeneration With Geographic Atrophy
Frequently asked questions
Who is developing vonaprument?
vonaprument is being developed by Annexon, Inc..
How many clinical trials involve vonaprument?
BioSniper tracks 1 clinical trial involving vonaprument.
Get deeper analysis on vonaprument
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis